Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown

Executive Summary

Exelixis's Cabometyx has been submitted for accelerated approval in first-line kidney cancer, adding to the drug's good news after disappointing interim Phase III results for the Bristol-Myers Opdivo/Yervoy combo.


Related Content

FDA Approval Round Up: Keytruda, Opdivo Add Claims
Liver Cancer: What's Close To The Market
Another Opdivo Disappointment For BMS, This Time In Kidney Cancer
Takeda Adds Exelixis Arrow To Oncology Quiver
Exelixis Hopes CABOSUN Means New Dawn For Cabometyx In Frontline Kidney Cancer
Exelixis' Strong Cabometyx Start Signals Changing Of Guard In Kidney Cancer Market
Kidney Cancer Gets A Double Uplift From Latest CHMP Meeting
Value Measures, Side Effects Help Differentiate Drugs In Crowded Kidney Cancer Market
Exelixis’ Cabozantinib Cleared For Kidney Cancer, With Competitive Labeling
Exelixis gains US OK for Cometriq in metastatic medullary thyroid cancer


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts